Picture of Medacta SA logo

MOVE — Medacta SA News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength

Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength


Overview

  • Switzerland medical device maker's H1 2026 revenue grew 9.7% in constant currency

  • Adjusted EBITDA margin for H1 2026 was 27.8% in constant currency

  • Net profit declined yr/yr due to one-off gain in prior year


Outlook

  • Medacta targets 2026 revenue growth of 10% to 14% in constant currency

  • Company expects 2026 adjusted EBITDA margin to expand by around 50bps vs prior year

  • Medacta sees 2024–2027E revenue CAGR of 12% to 15% in constant currency


Result Drivers

  • GEOGRAPHIC GROWTH MIX - Double-digit revenue growth in Asia Pacific and EMEA, with slower growth in North America due to US market softening and sales channel transition in Spine

  • PRODUCT INNOVATION - Growth in Hip, Knee, and Extremities segments attributed to new technologies such as AMIS platform, NextAR AR navigation, and GMK SpheriKA implants

  • NEW SURGEON ADOPTION - Increased revenues from new surgeon activities across all business lines, especially in US ambulatory surgery centers and academic centers


Company press release: ID:nEQ5Lj6X1a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Adjusted EBITDA

EUR 97 mln

H1 Adjusted EBITDA Margin

27.80%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Medacta Group SA is CHF180.00, about 46.8% above its September 8 closing price of CHF122.60

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 29 three months ago


Reuters Recommended Reads

  • Sept 8 - Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medacta SA

See all news